首页> 美国卫生研究院文献>Diagnostics >Comparison of Two Different Semiquantitative Urinary Dipstick Tests with Albumin-to-Creatinine Ratio for Screening and Classification of Albuminuria According to KDIGO. A Diagnostic Test Study
【2h】

Comparison of Two Different Semiquantitative Urinary Dipstick Tests with Albumin-to-Creatinine Ratio for Screening and Classification of Albuminuria According to KDIGO. A Diagnostic Test Study

机译:kdigo根据kdigo筛选和分类白蛋白 - 肌酐比的两种不同半定量尿尿布试验。诊断测试研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Semiquantitative dipstick tests are utilized for albuminuria screening. Methods: In a prospective cross-sectional survey, we analyzed the diagnostic test validity of the semiquantitative colorimetric indicator-dye-based Combur9-Test® and the albumin-specific immunochromatographic assay Micral-Test® for the detection of albuminuria, the distribution of the semiquantitative measurements within the albuminuria stages according to KDIGO, and the utility for albuminuria screening compared with an albumin-to-creatinine ratio (ACR) in a walk-in population. Results: In 970 subjects, albuminuria (≥30 mg/g) was detected in 12.7% (95% CI 85.6–96.3%) with the ACR. Sensitivity was 82.9% (95% CI 75.1–89.1%) and 91.9% (95% CI 88.7–96.9%) and specificity 71.5% (95% CI 68.4–74.6%) and 17.5% (95% CI 15.0–20.2%) for the Combur9-Test® and Micral-Test®, respectively. Correct classification to KDIGO albuminuria stages A2/A3 with the Combur9-Test® was 15.4%, 51.4%, and 87.9% at cut-offs of 30, 100, and ≥300 mg/dL, and with the Micral-Test® it was 1.8%, 10.5%, and 53.6% at cut-offs of 2, 5, and 10 mg/dL, respectively. Overall, disagreement to KDIGO albuminuria was seen in 27% and 73% with the Combur9-Test® and Micral-Test®, respectively. From the total population, 62.5% and 15.3% were correctly ruled out and 2.2% and 1% were missed as false-negatives by the Combur9-Test® and Micral-Test®, respectively. Conclusion: Compared to the Combur9-Test®, the utility of the Micral-Test® is limited, because the fraction of correctly ruled out patients is small and a large proportion with a positive Micral-Test® require a subsequent ACR conformation test.
机译:背景:用于白蛋白尿筛选的半阳性Dipstick试验。方法:在预期横截面调查中,我们分析了基于半阳性比色指示剂 - 染料的CombuR9-Test®和白蛋白特异性免疫层析测定MICral-Test®的诊断测试有效性,用于检测白蛋白尿,分布根据KDIGO的白粉蛋白尿阶段中的半定量测量,以及与携带犬群中的白蛋白 - 肌酐比(ACR)相比的鉴定性筛选的效用。结果:970个受试者中,用ACR以12.7%(95%CI 85.6-96.3%)检测白蛋白尿(≥30mg/ g)。敏感性为82.9%(95%CI 75.1-89.1%)和91.9%(95%CI 88.7-96.9%)和特异性71.5%(95%CI 68.4-74.6%)和17.5%(95%CI 15.0-20.2%)对于Combur9-Test®和MICRAL-TEST®。对kdigo白蛋白尿阶段的正确分类A2 / A3与CombuR9-Test®的截止值为30,100和≥300mg/ dL的截止值为15.4%,51.4%和87.9%,并使用MICRAL-TEST®在2,5和10mg / dl的截止值下,1.8%,10.5%和53.6%。总体而言,分别在27%和73%的kdigo白蛋白尿中分别与CombuR9-Test®和MICRAL-Test®看到了分歧。从总人口,62.5%和15.3%被正确排除,分别由CombuR9-Test®和MICRAL-Test®错过2.2%和1%。结论:与CombuR9-Test®相比,MICRAL-TEST®的效用是有限的,因为正确排除的患者的分数小,并且含有正微型-TEST®的大部分需要随后的ACR构象试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号